- *.- Johnson & Johnson's Janssen's unit said data on Rybrevant (amivantamab) indicated the biologic showed long-term efficacy and safety.
- *.- After a median follow-up of 19.2 months, the median overall survival (OS) with Rybrevant was 23 months, while two-year OS was 47%.
- *.- The objective response rate was 37% with a median duration of response of 12.5 months and median progression-free survival of 6.9 months.
- *.- No new safety signals were recorded.
- *.- The results were presented at the European Lung Cancer Congress.
- *.- Read why Seeking Alpha contributor Jonathan Weber recently called J&J (NYSE:JNJ) a buy . ...
